These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19862499)

  • 1. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
    Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
    Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A;
    J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.
    Watson AM; Soro-Paavonen A; Sheehy K; Li J; Calkin AC; Koitka A; Rajan SN; Brasacchio D; Allen TJ; Cooper ME; Thomas MC; Jandeleit-Dahm KJ
    Diabetologia; 2011 Mar; 54(3):681-9. PubMed ID: 21161164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.
    Watson AM; Li J; Samijono D; Bierhaus A; Thomas MC; Jandeleit-Dahm KA; Cooper ME
    Atherosclerosis; 2014 Aug; 235(2):444-8. PubMed ID: 24945577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.
    Hoekman J; Lambers Heerspink HJ; Viberti G; Green D; Mann JF; de Zeeuw D
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):490-8. PubMed ID: 24408122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse.
    Chew P; Yuen DY; Stefanovic N; Pete J; Coughlan MT; Jandeleit-Dahm KA; Thomas MC; Rosenfeldt F; Cooper ME; de Haan JB
    Diabetes; 2010 Dec; 59(12):3198-207. PubMed ID: 20823099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
    Baltatu OC; Zaugg CE; Schumacher C; Louie P; Campos LA; Bader M
    Pharmacol Res; 2014 Feb; 80():9-13. PubMed ID: 24368192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice.
    Menini S; Iacobini C; Ricci C; Blasetti Fantauzzi C; Pugliese G
    Diabetologia; 2015 Apr; 58(4):845-53. PubMed ID: 25471794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
    Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
    J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avosentan for overt diabetic nephropathy.
    Mann JF; Green D; Jamerson K; Ruilope LM; Kuranoff SJ; Littke T; Viberti G;
    J Am Soc Nephrol; 2010 Mar; 21(3):527-35. PubMed ID: 20167702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.
    Koïtka A; Cao Z; Koh P; Watson AM; Sourris KC; Loufrani L; Soro-Paavonen A; Walther T; Woollard KJ; Jandeleit-Dahm KA; Cooper ME; Allen TJ
    Diabetologia; 2010 Mar; 53(3):584-92. PubMed ID: 19957160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
    J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.
    Watson AM; Gray SP; Jiaze L; Soro-Paavonen A; Wong B; Cooper ME; Bierhaus A; Pickering R; Tikellis C; Tsorotes D; Thomas MC; Jandeleit-Dahm KA
    Diabetes; 2012 Aug; 61(8):2105-13. PubMed ID: 22698914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.
    Oguiza A; Recio C; Lazaro I; Mallavia B; Blanco J; Egido J; Gomez-Guerrero C
    Diabetologia; 2015 Jul; 58(7):1656-67. PubMed ID: 25982245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk.
    Vandekerckhove L; Vermeulen Z; Liu ZZ; Boimvaser S; Patzak A; Segers VF; De Keulenaer GW
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E495-504. PubMed ID: 26786778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.